Unknown PHASE2 INTERVENTIONAL 1-arm NCT05448183

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

Sponsor: Xuhua Duan

Conditions Extrahepatic Cholangiocarcinoma

Interventions Toripalimab, Gemcitabine,Oxaliplatin

Updated 4 times since 2022 Last updated: Jul 1, 2022 Started: Jun 15, 2022 Primary completion: May 15, 2023 Completion: May 15, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Extrahepatic Cholangiocarcinoma and is currently ongoing. Xuhua Duan leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Aug 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xuhua Duan

Data source: The First Affiliated Hospital of Zhengzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China